Fig. 5

Immune infiltration landscape and checkpoint immunotherapy response in tumors. A Immune cell infiltration calculated using multiple computational methods in tumors. Wilcoxon test P-value was attached behind the cell name. B Multiple immune and TME signatures calculated using the IOBR method in tumors. Wilcoxon P-value was attached behind the cell name. C GSEA indicates an enhanced immune phenotype enriched in astrocytoma. D TME and tumor-related scores quantified using ESTIMATE/ABSOLUTE algorithms (Wilcoxon rank-sum test). High immune score and inflammation score indicates infiltrative immune cells, high stromal score indicated large proportion of stromal cells, higher TME score indicates large proportion of nontumor cells (primarily immune + stromal cells), high tumor index indicates great tumor malignancy and progression. E Correlation between tumor purity and immune cell function. Spearman R with p-values presented. A, astrocytoma, O, oligodendroglioma. F Astrocytoma had a lower TIDE score than oligodendroglioma. G Astrocytoma had a higher IPS score than oligodendroglioma. H Astrocytoma had higher relative PD-L1 expression than oligodendroglioma. I Oligodendroglioma had a higher level of T cell exclusion (***Wilcoxon P < 0.001; ****P < 0.0001). J The proportion of immunotherapy responders and nonresponders between astrocytoma and oligodendroglioma, Chi-square test P < 0.001 (***P < 0.001). ICI, immune checkpoint inhibitor